BIT's 18th Annual Congress of International Drug Discovery Science and Technology (IDDST-2023)

Conference Report

The Cluster Meeting of Gala Technology 2023 (Galatech-2023) which was held in Holiday Inn Amsterdam Arena Towers on July 12-14, achieved a consummation. This scientific cluster gathering consisted of four parallel conferences together, which are The 18th Annual Congress of International Drug Discovery Science and Technology, The 9th Annual International Symposium of Drug Delivery Systems, The 8th Annual Conference of AnalytiX and The 13th Anniversary of Protein & Peptide Conference. The cluster meeting hosted by World High Technology Society, operated by BIT Group Global, sponsored by Wyatt Technology Division of Waters and supported by International Transmembrane Transporter Society, International Society of Digital Medicine, The Asian Society of Natural Products, UK Pharmacogenetics and Stratified Medicine Network, The Czech Pharmaceutical Society and The National Hospital Pharmacists Association of Romanian. This annual conference brought together nearly 200 specialists from 36 countries and regions.

The Opening Ceremony and Keynote Forum took place on Wednesday’s morning, the keynote forum is sponsored by Wyatt Technology Division of Waters. Dr. Stefan Platz, SVP & Global Head Clinical Pharmacology & Safety Sciences, AstraZeneca, UK, Dr. Luc Van Hijfte, Senior VP Drug Discovery, Symeres B.V., the Netherlands, Dr. Matthew He, Professor, Halmos College of Arts and Sciences, Nova Southeastern University, USA, Dr. Balazs Sarkadi, Professor Emeritus, Research Centre for Natural Sciences, Institute of Enzymology, Hungary, Dr. Roger Scherrers, Head of Analytical Service, Waters, Wyatt Technology Division, Germany, Dr. Robert Kaptein, Emeritus Professor, Bijvoet Center for Biomolecular Research, Utrecht University, the Netherlands and Dr. Matthias von Herrath, Scientific Director of the Diabetes Research Institute, University of Miami School of Medicine; Vice President, Novo Nordisk, USA gave brilliant plenary speeches. Dr. Matthew He as moderators of the Opening Ceremony and Keynote Forum expressed great gratitude to the presence of all delegates, speakers and participants and particularly wished all the guests a memorable stay in Amsterdam on behalf of the organizing committee.

Plenary Forum

The unique program of Galatech2023 comprised 16 parallel sessions. Hot topics and new ideas on Drug Discovery, Drug Delivery Systems, AnalytiX and Protein & Peptide were hotly discussed and exchanged by presenters and visitors in the three-day’s diversified program.

Parallel Sessions

Before, during and after the conference, we received warm support and valuable suggestions from the delegates on how to better plan and organize the next conference. Depending on the warmly support and good suggestions from all of the participants, we are quite confident in organizing Galatech-2024 which would be better and more successful. All of us are looking forward to meeting you again in 2024.

Welcome Banquet

Keynote Speakers

	Dr. Stefan Platz, SVP & Global Head Clinical Pharmacology & Safety Sciences, AstraZeneca, USA		Dr. Luc Van Hijfte, Senior VP Drug Discovery, Symeres, the Netherlands
	Dr. Matthew He, Professor, Halmos College of Arts and Sciences, Nova Southeastern University, USA		Dr. Balazs Sarkadi, Professor Emeritus, Institute of Enzymology, Hungary
	Dr. Roger Scherrers, Head of Analytical Service, Waters, Wyatt Technology Division, Germany		Dr. Robert Kaptein, Emeritus Professor, Bijvoet Center for Biomolecular Research, Utrecht University, The Netherlands
	Dr. Matthias von Herrath, Scientific Director of the Diabetes Research Institute, University of Miami School of Medicine; Vice President, Novo Nordisk, USA

Confirmed Renowned Speakers

Dr. Pirouz M, Daftarian, Director of Scientific Engagement, Crown Biosciences and MBLI, USA	Dr. Volker Lang, Managing Director, AbCheck, Czech Republic	Dr. Thijs (Mattheus) Paulus van Iersel, Senior Director of Clinical Pharmacology, Scientific Affairs - Clinical Pharmacology, PRA Health Sciences, The Netherlands
Dr. Iain L. O. Buxton, Foundation Professor, University of Nevada, USA	Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France	Dr. Loui Madakamutil, SVP, Head of Biology and Preclinical Development, Nektar Therapeutics, USA
Dr. Marcus Bauser, Director, Medicinal Chemistry, Bayer AG, Germany	Dr. Henk Leeuwis, Vice President, LioniX International, the Netherlands	Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, BoehringerIngelheim, Germany
Dr. Juhaeri JUHAERI, Vice President and Head, Epidemiology and Benefit-Risk Evaluation, Sanofi, USA	Dr. Mehrdad Ghashghaeinia, Professor, University Medical Center Schleswig-Holstein, Germany	Dr. Erminia Massarelli, Professor, City of Hope, USA
Dr. Stefan J. Platz, Senior Vice President, AstraZeneca, UK	Dr. John J. Miles, Professor, James Cook University, Australia	Dr. Daniel Bradley, Associate Director, Biogen, USA
Dr. Immanuel Lerner, Chief Executive Officer, Pepticom LTD, Isreal	Dr. Anthony W. Coleman, Research Director, Université de Lyon, France	Dr. Mircea Ciuca, Head, Medical Clinical Drug Safety, ViforPharma, Switzerland
Dr. Lucas P.J.J. Noldus, Founder & CEO, Noldus Information Technology bv, the Netherlands	Dr. Wilbur de Kruijf, VP, MedsprayPharma, the Netherlands	Dr. Hubert Pellikaan, NextstepPharma BV, the Netherlands
Dr. Faz Chowdhury, CEO, NemauraPharma Limited, UK	Dr. Joël Richard, Head of Technical and Pharmaceutical Operations, MedinCell, France	Dr. Khursheed Anwer, Executive Vice President & Chief Science Officer, Celsion Corporation, USA
Dr. Michael Gamlen, Chief Scientific Officer, Gamlen Tableting Ltd., UK	Dr. Michael Black, Head of Sales PHARMA, BENEO-Palatinit GmbH, Germany	Dr. Masha Poyurovsky, VicePresident, Kadmon Corporation, LLC, USA
Dr. Yaakov Naparstek, Professor of Medicine, Hadassah University Hospital, Israel	Dr. Michael Reilly, Executive Director, Alliance for Safe Biologic Medicine, USA	Dr. Luana Pesco Koplowitz, Chief Medical & Scientific Officer, DUCK FLATS Pharma, USA
Dr. Tom Mander, Chief Operating Officer, Domainex Ltd, UK	Dr. Lars Neumann, Director, Proteros biostructures GmbH, Germany	Dr. Raphael Serreau, Professor, Unité INSERM “Psycomadd“ Université Paris Sud, France
Dr. Sigrid Saaler-Reinhardt, Director, Midas Pharma GmbH, Germany	Dr. Monica Berrondo, CEO, Macromoltek - Molecular simulations simplified, USA	Dr. Andrea Cusack, CBO, Leon-nanodrugs GmbH, Germany
Dr. Hiroyuki Fukase, Director, Clinical Research Center, Clinical Research Hospital Tokyo, Japan	Dr. Didier Dubreuil, Professor, University of Nantes, France	Dr. Gilles Courtemanche, Associate Director, Antimicrobials Unit, BIOASTER, France
Dr. Eduard Stefan, Head, Institute of Biochemistry, University of Innsbruck, Austria	Dr. Albin (Jim) Nelson, Senior Principal/Owner, Schwegman Lundberg Woessner P.A., USA	Dr. Isaac Bright, Chief Executive Officer, RubrYc Therapeutics, Inc, USA
Dr. Anna Birukova, Professor of Medicine, University of Maryland, USA	Dr. Konstantin Birukov, Professor of Anesthesiology, University of Maryland, USA	Dr. Ralf Glatthar, Director, Novartis Pharma AG, Switzerland
Dr. Barry Morgan, CSO, Hitgen Ltd., USA	Dr. Roberta Bursi, Vice President R&D, InSilicoTrials Technologies, Italy	Dr. Sergey Suchkov, Director of The Center for Personalized Medicine, I.M. Sechenov First Moscow State Medical University, Russia
Dr. Michael Ovadia, Professor, Tel Aviv University, Israel	Dr. Lakshminarayan R. Ranganath, Professor, University of Liverpool, UK	Dr. Karin Schutze, CSO, CellTool GmbH, Germany
Dr. Andrew Hanneman, Associate Director, Mass Spectrometry, Charles River Laboratories, USA	Dr. Steven van Helden, Chief Technology Officer, Pivot Park Screening Centre B.V., Netherlands	Dr. Elaine M. Hull, Professor, Florida State University, USA

Exhibition and Poster

IDDST-2023 provides an ideal platform to showcase your novel technologies and products in the Netherlands. It is developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent repeated opportunities for delegates to visit the exhibits.

Why Reserve a Booth at IDDST-2023
• To Meet Face-to-Face with the International Movers and Shakers
• To Meet with Key Decision Marker
• To Explore Business Opportunities
• To Spotlight Advanced Technologies and Their Scientific and Commercial Applications
• To Take Advantage of the Conference's Captive Audience and Networking Opportunities within the Exhibition Hall

Exhibition Date:
Set-up date: July 11, 2023
Show dates: July 12-14, 2023
Place: Amsterdam, the Netherlands

Exhibitors

Wyatt Technology

CellTool GmbH

Introduction to Amsterdam

Amsterdam is the capital city and most populous municipality of the Netherlands. Its status as the capital is mandated by the Constitution of the Netherlands. Amsterdam's main attractions include its historic canals, the Rijksmuseum, the Van Gogh Museum, the Stedelijk Museum, Hermitage Amsterdam, the Anne Frank House, the Scheepvaartmuseum, the Amsterdam Museum, the Heineken Experience, the Royal Palace of Amsterdam, Natura Artis Magistra, Hortus Botanicus Amsterdam, NEMO, the red-light district and many cannabis coffee shops. They draw more than 5 million international visitors annually. The city is also well known for its nightlife and festival activity; several of its nightclubs (Melkweg, Paradiso) are among the world's most famous. It is also one of the world's most multicultural cities, with at least 177 nationalities represented.

Conference Chairman